"Evidence indicates that in people with idiopathic Parkinson’s, [...] the LRRK2 protein is overly active, regardless of [...] whether or not they have a mutated LRRK2."
"Molecules that block the activity of the LRRK2 kinase [...] are currently being tested in clinical trials."
parkinsonsnewstoday.com/201...
Research paper: LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease (2019)
Now I remember why this sounded familiar. MJFF had an article on this research about a week ago.
michaeljfox.org/news/new-fi...
A recent PNT article (September 2019) gave an update on Denali's progress in clinical trials of its LRRK2 kinase inhibitors DNL201 and DNL151.
I was accepted to be part of the DNL201 drug this last spring. It looks promising. I went
To start the trial when I was disqualified for a then unknown heart defect I have.
I see from the trial record on the Clinical Trials website that they are still recruiting, even though the trial was due to finish in September. In the exclusion criteria they mention "clinically significant" issues involving the lungs, but not the heart, as far as I can see. Still, something spooked them, obviously.
I think Denali has two different drugs that they are trying. Here is an interesting bit of information. At our last support group meeting we had a neurologist speaking on some of the clinical trials they were running. One thing he mentioned that I found to be exciting was the fact that ONE patient had complete relief of his PD symptoms when he was treated with the lrrk2 inhibitor . He said that as far as he knew this patient didn't even have the lrrk2 mutation. He also said that the symptoms returned once the medication was stopped. He didn't give any details outside of what I mentioned here but he confirmed that this was part of the lrrk2 clinical trial.
Clinical trial suggests Parkinson's drug is safe in humans
Phase 4 study to evaluate efficacy of orally administrated Trehalose in individuals with idiopathic & LRRK2-associated Parkinsons
Gold Nanoparticles May Offer Benefit To People With PD By Reducing Brain Deficits
GOOGLE's Founder gives 127 MILLION $$$ to Michael J. Fox Foundation!
Parkin, glutamate, NAC, mitophagy
